Cargando…

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

IMPORTANCE: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Hengwei, Shi, Jimin, Luo, Yi, Tan, Yamin, Zhang, Mingming, Lai, Xiaoyu, Yu, Jian, Liu, Lizhen, Fu, Huarui, Huang, He, Zhao, Yanmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841467/ https://www.ncbi.nlm.nih.gov/pubmed/33502484 http://dx.doi.org/10.1001/jamanetworkopen.2020.34750

Ejemplares similares

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
por: Zhao, Yanmin, et al.
Publicado: (2021)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin–Based T-Cell–Replete Haploidentical Hematopoietic Stem Cell Transplant
por: Wu, Hengwei, et al.
Publicado: (2022)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
por: Rashidi, Armin, et al.
Publicado: (2023)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation
por: Park, Joo Han, et al.
Publicado: (2014)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients
por: Dang, Si-Hua, et al.
Publicado: (2020)

Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant
por: Patel, Dilan A., et al.
Publicado: (2021)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies
por: Zhang, Meng-yun, et al.
Publicado: (2022)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease
por: Tijaro-Ovalle, Natalia M., et al.
Publicado: (2019)

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2020)

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
por: Bonig, Halvard, et al.
Publicado: (2023)

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2021)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation
por: Castilla-Llorente, Cristina, et al.
Publicado: (2014)

Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation
por: Xu, Xiaoxiao, et al.
Publicado: (2021)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023)

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
por: Lin, Yan, et al.
Publicado: (2023)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
por: Locatelli, Franco, et al.
Publicado: (2023)

Adiponectin and resistin in acute and chronic graft-vs-host disease patients undergoing allogeneic hematopoietic stem cell transplantation
por: Robak, Oliver, et al.
Publicado: (2016)

Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease
por: Le Bastard, Quentin, et al.
Publicado: (2021)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
por: Robin, Marie, et al.
Publicado: (2021)

Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
por: Chen, Xiaomei, et al.
Publicado: (2015)

Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

2844. Butyrogenic Bacteria After Acute Graft vs. Host Disease Associate with the Development of Steroid Refractory GVHD
por: Golob, Jonathan L, et al.
Publicado: (2019)

Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Yang, Kaibo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btk698gs7mcg7k7pd2t6nr1jt6